| dc.contributor.author | Tripathi, Chakrapani | |
| dc.contributor.author | Tewari, B N | |
| dc.contributor.author | Kanchan, R K | |
| dc.contributor.author | Baghel, K S | |
| dc.contributor.author | Nautiyal, Naveen | |
| dc.contributor.author | Shrivastava, Richa | |
| dc.contributor.author | Kaur, Harbeer | |
| dc.contributor.author | Bhatt, M L B | |
| dc.contributor.author | Bhadauria, Smrati | |
| dc.date.accessioned | 2014-12-04T09:18:54Z | |
| dc.date.available | 2014-12-04T09:18:54Z | |
| dc.date.issued | 2014 | |
| dc.identifier.citation | Oncotarget 2014, 5(14), 5350-68 | en |
| dc.identifier.uri | http://hdl.handle.net/123456789/1424 | |
| dc.description.abstract | TAMs, a unique and distinct M2-skewed myeloid population of tumor stroma, exhibiting pro-tumor functions is fast emerging as a potential target for anti-cancer immunotherapy. Macrophage-recruitment and M2-polarization represent key TAMs-related phenomenon that are amenable to therapeutic intervention. However successful translation of these approaches into effective therapeutic regimen requires better characterization of tumor-microenvironment derived signals that regulate macrophage recruitment and their polarization. Owing to hypoxic milieu being a persistent feature of tumor-microenvironment and a major contributor to malignancy and treatment resistance, the current study was planned with an aim to decipher tumor cell responses to hypoxia vis-a-vis macrophage homing and phenotype switching. Here, we show that hypoxia-primed cancer cells chemoattract and polarize macrophages to pro-angiogenic M2-polarized subtype via Eotaxin and Oncostatin M. Concordantly, hypoxic regions of human breast-cancer specimen exhibited elevated Eotaxin and Oncostatin M levels with concurrently elevated M2-macrophage content. Blockade of Eotaxin/Oncostatin M not only prevented hypoxic breast-cancer cells from recruiting and polarizing macrophages towards an M2-polarized phenotype and retarded tumor progression in BalbC/4T1-syngenic-mice-model of breast-cancer but also enhanced the efficacy of anti-angiogenic Bevacizumab. The findings established these two cytokines as novel targets for devising effective anticancer therapy particularly for tumors that are refractory or develop resistance to anti-angiogenic therapeutics. | en |
| dc.format.extent | 3016276 bytes | |
| dc.format.mimetype | application/pdf | |
| dc.language.iso | en | en |
| dc.relation.ispartofseries | CSIR-CDRI Communication No. 8714 | en |
| dc.subject | Hypoxia | en |
| dc.subject | M2Polarization | en |
| dc.subject | TAM | en |
| dc.subject | Tumor-microenvironment | en |
| dc.subject | Chemoattract | en |
| dc.subject | Pro-angiogenic | en |
| dc.subject | Breast Cancer | en |
| dc.title | Macrophages are Recruited to Hypoxic Tumor Areas and Acquire a Pro-Angiogenic M2-Polarized Phenotype via Hypoxic Cancer Cell Derived Cytokines Oncostatin M and Eotaxin | en |
| dc.type | Article | en |